Leukemia News and Features

Asparaginase Erwinia chrysanthemi (Erwinaze)

January 26, 2012

Asparaginase Erwinia chrysanthemi is a component of a multiagent regimen for the treatment of acute lymphoblastic leukemia in patients with a hypersensitivity to Escherichia coli-derived asparaginase.
 

Cutaneous melanoma begets cutaneous melanoma

Delicia Honen Yard January 06, 2012

Continued skin surveillance is important for survivors of cutaneous melanoma (CM), indicate findings showing that this is the most common second primary cancer among persons with a first CM.
 

Addition of vorinostat yields high remission rate in AML study

Delicia Honen Yard December 28, 2011

An 85% remission rate was noted in a group of patients with acute myeloid leukemia who received the histone deacetylase inhibitor vorinostat in addition to cytarabine and idarubicin.
 

Exploring holistic medicine: Using acupuncture to relieve cancer-related fatigue

December 19, 2011

The ancient Eastern medicinal art can relieve one of the most distressing effects of cancer and cancer treatment: fatigue.
 

FDA Update: December 2011

December 19, 2011

In November and December 2011, the FDA approved a number of new cancer drugs. Highlights include cetuximab for head and neck cancer, Hemacord, and asparaginase Erwinia chrysanthemi for ALL.
 

CDC focuses on infection prevention

December 16, 2011

A new initiative launched by CDC is designed to reduce the risk of life-threatening infection in cancer patients undergoing chemotherapy.
 

High rate of leukemia in elderly may be due to stem cell aging

Delicia Honen Yard December 13, 2011

Hematopoietic stem cells from healthy persons older than 65 years make fewer immunoprotective lymphocytes than do stem cells from healthy persons aged 20 to 35 years.
 

Existing antibiotic may help fight leukemia

Delicia Honen Yard December 02, 2011

The IV antimicrobial tigecycline, indicated for the treatment of various infections, targets and destroys leukemia stem cells by cutting off the cell's energy production.
 

Older blood cancer patients may benefit from cell transplant regimen

Delicia Honen Yard November 22, 2011

A regimen using minimal-intensity radiation therapy before bone marrow or stem cell transplantation may work for older patients who cannot tolerate stronger pretransplant treatment.
 

Finding Emotional Support for Long-term Illness

November 16, 2011

Advances in medications to treat long-term illnesses have allowed patients to live with their disease for a long time. This fact sheet provides hints for managing the emotional challenges of coping with CML over time.
 

Leukemia Clinical Trials

Clinical Trial: EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)

Clinical Trial: Direct Measurement of Leukemic Cell Turnover (Synthesis and Removal) in Patients With Chronic Lymphocytic Leukemia (CLL) Using Deuterated Water

Clinical Trial: Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

Clinical Trial: Multi-center Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Clinical Trial: Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia

Free CE from mycme.com

Discussions on Emerging Concepts and Controversies in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer

2.00 / AMA PRA Category 1 Credit(s)TM
This program reviews developments in maintenance therapy and evaluates the relevance of tumor histology and biomarker analysis for the management of NSCLC patients.
 

Cancer care is expensive.
CancerCare can help.


Connect Booklets
Visit Reflections for first-hand stories on the power of the patient to impact caregivers in oncology nursing.
 Subscribe to the RSS for this page  [view all our RSS feeds here]

Web Exclusives

Psychosocial approach useful in managing cancer pain

February 03, 2012

Psychosocial interventions, including skills instruction and education, can help reduce pain in persons with cancer, confirm the results of a recent meta-analysis.
 

Experimental agent slows progression of colorectal cancer

February 02, 2012

The investigational drug regorafenib conferred a statistically significant survival benefit in patients with metastatic colorectal cancer in whom no standard therapy was effective.
 

In HER2 breast cancer, lapatinib works better with trastuzumab than without

February 01, 2012

Lapatinib is not as effective as trastuzumab against (HER2)-positive breast cancer, but combining the two nearly doubles the effectiveness seen with either one alone.
 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions